21日上午，北京大学与普洛药业股份有限公司共建“北京大学—普洛药业核酸药物与生物制造联合实验室”签约揭牌仪式在北京大学英杰交流中心星光厅举行。双方将围绕小核酸原料药化学与生物合成开展产学研协同攻关，推动高校基础研究优势与企业产业化转化能力深度融合，为普洛药业CDMO业务在核酸药物与生物制造领域拓展提供技术支撑。

北京大学科技开发部部长姚卫浩，科技开发部副部长郑如青，生命科学学院院长陈雪梅，化学与分子工程学院副院长陈继涛，化学与分子工程学院教授雷晓光，未来技术学院教授汪阳明，以及横店集团助理总裁、普洛药业股份有限公司董事长祝方猛携高管团队出席签约揭牌仪式。仪式由雷晓光教授主持。

北京大学科技开发部副部长郑如青

郑如青副部长在发言指出，北京大学始终高度重视基础研究与科技创新，积极发挥多学科交叉融合的优势，推动科技创新与产业创新深度融合。当前核酸药物和生物制造前景广阔，双方共建联合实验室是高校科研优势与企业产业化能力的有机结合。希望双方围绕关键科学问题和核心技术开展联合攻关，推动基础研究、原始创新与产业应用有效衔接，形成具有自主知识产权和应用潜力的创新成果。北京大学科技开发部将持续做好服务保障，推动合作走深走实。

北京大学生命科学学院院长陈雪梅

陈雪梅院长在发言时说，北京大学RNA研究中心已在RNA修饰、编辑、递送和小分子靶向RNA等方面形成研究基础。北京大学—普洛药业联合实验室是RNA中心首个校企联合实验室，双方将在化学与RNA交叉领域开展合作，共同探索从原始创新到产业应用的有效路径。

北京大学化学与分子工程学院副院长陈继涛

陈继涛副院长在发言时表示，化学学院科研团队长期面向学科前沿开展生物医药合成研究，积极推动科技成果转化。此次与普洛药业合作成立联合实验室，将为前沿研究成果与产业化能力对接提供平台，推动更多小分子核酸药物走向应用。

北京大学化学与分子工程学院教授雷晓光

雷晓光教授介绍了联合实验室的建设背景和重点方向。他表示，联合实验室将依托北京大学的研究基础优势，结合普洛药业的产业化能力，协同推进关键技术攻关和成果转化。

横店集团助理总裁、普洛药业董事长祝方猛

祝方猛董事长在发言时指出，普洛药业深耕医药健康三十余年，已发展成为涵盖CDMO服务、原料药、中间体及制剂的综合性医药上市企业，并持续布局核酸药物、合成生物学、连续流化学等前沿领域。前沿技术突破离不开基础研究支撑，此次携手北大，是学术界原始创新与产业界成果转化的深度对接，也是践行新质生产力的一次有益探索。希望双方以联合实验室为载体，把合作做实做深，在关键技术攻关、成果转化和人才培养上取得实际进展，为普洛药业CDMO业务在核酸药物与生物制造领域的拓展提供长期支撑。

在与会嘉宾共同见证下，雷晓光教授与祝方猛董事长签订合作协议，并共同为“北京大学—普洛药业核酸药物与生物制造联合实验室”揭牌。根据合作协议，联合实验室由北京大学化学与分子工程学院雷晓光教授担任主任，由北京大学生命科学学院陈雪梅教授和普洛药业股份有限公司庄程翰博士担任副主任，将聚焦原料药的化学与生物合成，重点围绕小核酸方向开展研究，实行项目化运作。

此次联合实验室的成立，是普洛药业持续深耕前沿创新赛道的重要举措。未来，双方将依托北京大学在生命科学、化学与分子工程等领域的基础研究优势，结合普洛药业在工程化放大、CMC及规模化生产、质量管理体系等方面的能力，共同推进关键技术攻关、成果转化和人才培养，推动更多科研成果走向产业化，助力中国生物医药向全球价值链高端攀升。

签约仪式结束后，与会人员围绕联合实验室建设和后续合作进行了交流，并走访参观了核酸药物与生物制造联合实验室和核糖核酸北京研究中心。

Peking University and Apeloa Pharmaceutical Co., Ltd. Establish Joint Laboratory for Nucleic Acid Drugs and Biomanufacturing

Beijing, China — Peking University and Apeloa Pharmaceutical Co., Ltd. have signed an agreement to establish the "Peking University–Apeloa Joint Laboratory for Nucleic Acid Drugs and Biomanufacturing." The signing and unveiling ceremony was held on the morning of October 21 at Yingjie Exchange Center, Peking University.

The joint laboratory will bring together the university's strengths in fundamental research with Apeloa's industrial-scale capabilities, focusing on collaborative R&D in chemical and biological synthesis of small nucleic acid drug substances. The partnership is designed to provide technical support for Apeloa's CDMO business expansion into nucleic acid drugs and biomanufacturing.

The ceremony was attended by senior representatives from both institutions, including Weihao Yao, Director of Peking University’s Office of Science and Technology Development; Ruqing Zheng, Deputy Director of the same office; Xuemei Chen, Dean of the School of Life Sciences; Jitao Chen, Associate Dean of the College of Chemistry and Molecular Engineering; Xiaoguang Lei, Professor at the College of Chemistry and Molecular Engineering; Yangming Wang, Professor at the College of Future Technology; and Brian Zhu, Assistant President of Hengdian Group and Chairman of Apeloa Pharmaceutical, along with Apeloa’s executive team. Professor Xiaoguang Lei presided over the ceremony.

Ruqing Zheng, Deputy Director of the same office, Peking University

Speaking at the ceremony, Ruqing Zheng noted that Peking University has long placed strong emphasis on fundamental research and technological innovation, leveraging its multidisciplinary strengths to integrate scientific advances with industrial applications. "Nucleic acid drugs and biomanufacturing hold tremendous promise. This joint laboratory represents a natural alignment between academic research excellence and industrial capability. We hope both sides will tackle key scientific questions and core technologies together, creating innovative outcomes with independent intellectual property and real application potential," Zheng said, adding that the university will continue to provide full support to ensure the partnership delivers tangible results.

Xuemei Chen, Dean of the School of Life Sciences, Peking University

Dean Xuemei Chen highlighted the foundation laid by Peking University's RNA Research Center, which has built expertise in RNA modification, editing, delivery, and small-molecule targeting of RNA. "This is the RNA Center's first joint laboratory with an industry partner. Together, we will explore how fundamental innovations in chemistry and RNA can find a genuine path to industrial application."

Jitao Chen, Associate Dean of the College of Chemistry and Molecular Engineering, Peking University

Jitao Chen noted that research teams at the College of Chemistry have long pursued cutting-edge work in pharmaceutical synthesis while actively advancing technology transfer. "This laboratory provides a platform where frontier research can connect directly with industrialization capabilities, helping more oligonucleotide-based therapeutics reach the clinic and the market."

Xiaoguang Lei, Professor at the College of Chemistry and Molecular Engineering, Peking University

Professor Xiaoguang Lei, who introduced the background and priorities of the laboratory, said the initiative will combine Peking University's research foundations with Apeloa's manufacturing expertise to accelerate key technology breakthroughs and commercialization.

Brian Zhu, Assistant President of Hengdian Group and Chairman of Apeloa Pharmaceutical

Chairman Brian Zhu emphasized Apeloa's three decades of experience in the pharmaceutical industry, noting that the company has grown into a listed, integrated pharmaceutical enterprise spanning CDMO services, active pharmaceutical ingredients (APIs), intermediates, and finished formulations, while actively investing in frontier areas such as nucleic acid drugs, synthetic biology, and continuous-flow chemistry.

"Breakthroughs in frontier technologies are built on the foundation of basic research. Partnering with Peking University is a deep convergence of original academic innovation with industrial translation—and a meaningful step toward fostering new quality productive forces," Brian said. "We hope both sides will make this partnership substantive and lasting, achieving real progress in technology development, commercialization, and talent cultivation—providing long-term support for Apeloa's CDMO expansion in nucleic acid drugs and biomanufacturing."

Under the agreement, the laboratory will be directed by Xiaoguang Lei, Professor at the College of Chemistry and Molecular Engineering, with Xuemei Chen, Dean of the School of Life Sciences, and Dr. Chenghan Zhuang of Apeloa Pharmaceutical serving as deputy directors. Operating on a project-based model, the laboratory will focus on chemical and biological synthesis of drug substances, with a primary emphasis on small nucleic acids.

The establishment of the joint laboratory marks another important step in Apeloa's sustained commitment to frontier innovation. Going forward, the two partners will combine Peking University's strengths in life sciences and chemistry with Apeloa's capabilities in process scale-up, CMC, large-scale manufacturing, and quality management systems—advancing key technologies, accelerating the translation of research outcomes into commercial products, and training the next generation of talent. Together, they aim to help China's biopharmaceutical industry move up the global value chain.

Following the ceremony, attendees held discussions on the laboratory's development and future collaboration, and toured the joint laboratory facilities and the Beijing Research Center for Ribonucleic Acid.

出 品 人  ：祝方猛

主     编  ：聂文彬

往期精彩推荐

立 即 扫 码 关 注 

普洛大药房旗舰店

@ 京 东